Medical Devices APAC

APAC Diabetes Care Devices Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

APAC Diabetes Care Devices Market Industry Trends and Forecast to 2034: Segmented by (Product type, Device Type, Delivery Type, Distribution Channel, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

APAC · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $9.59 Bn Placeholder estimate
Estimate 2025 $10.27 Bn 21.5% of the global market
Projected 2034 $19.16 Bn 86.5% Adds $8.89 Bn over 9 forecast years
CAGR 2025–2034 7.17% Faster than 12% of 173 Medical Devices markets here
Key players 10 +5
  • APAC is 21.51% of the global market.
  • Among regions, the largest is North America at $23.44 Bn.
  • Fastest growing: Africa at 7.4% a year.
  • APAC ranks 2nd of 6 by size among regions.

Market size projection

APAC

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$8.89 Bn total, 2026–2034

Year-by-year market size, 2024–2034
Diabetes Care Devices Market market size by year, APAC
YearMarket sizeChange that yearSince 2025
2024 (estimate) $9.59 Bn — —
2025 (base) $10.27 Bn +$687.4 Mn —
2026 (forecast) $11.01 Bn +$736.7 Mn +7.2%
2027 (forecast) $11.80 Bn +$789.5 Mn +14.9%
2028 (forecast) $12.65 Bn +$846.1 Mn +23.1%
2029 (forecast) $13.55 Bn +$906.8 Mn +31.9%
2030 (forecast) $14.53 Bn +$971.8 Mn +41.4%
2031 (forecast) $15.57 Bn +$1.04 Bn +51.5%
2032 (forecast) $16.68 Bn +$1.12 Bn +62.4%
2033 (forecast) $17.88 Bn +$1.20 Bn +74%
2034 (forecast) $19.16 Bn +$1.28 Bn +86.5%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

APAC Diabetes Care Devices Market Analysis at a glance
Market size, 2025$10.27 Bn placeholder estimate
Forecast, 2034$19.16 Bn placeholder estimate
Growth (CAGR), 2025–20347.17% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsProduct type, device type, delivery type and distribution channel (see all)
Key playersMedtronic, Abbott Laboratories, Dexcom, Inc., Roche Diabetes Care, Novo Nordisk A/S and 5 more (see all)
Active clinical trials144 in Asia PacificSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Asia Pacific. Retrieved 9 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The APAC Diabetes Care Devices Market Analysis Executive Summary

The Diabetes Care Devices Market encompasses a range of medical devices specifically designed to assist individuals in managing their diabetes effectively. This includes devices for monitoring blood glucose levels, administering insulin, and overall diabetes management. The market is crucial for helping patients avoid complications associated with diabetes, such as kidney failure, heart disease, and vision loss. The increasing prevalence of diabetes globally, driven by factors such as rising obesity rates and sedentary lifestyles, is propelling the demand for these devices.

Key segments within the diabetes care devices market include blood glucose monitoring devices, such as self-monitoring blood glucose meters and continuous glucose monitors, as well as insulin delivery devices like insulin pens and pumps. The integration of smart technology into these devices is transforming diabetes management, making it more convenient and effective for patients. Additionally, the market is characterized by a competitive landscape with major players like Abbott Laboratories, Medtronic, and Becton, Dickinson and Company, continuously innovating to enhance their product offerings and improve patient outcomes.

Bar chart: Asia Pacific Diabetes Care Devices market size, 2024–2034, placeholder estimates. $9.59 Bn in 2024, $10.27 Bn in 2025 and $19.16 Bn in 2034, 7.17% CAGR.
Asia Pacific Diabetes Care Devices market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

APAC Diabetes Care Devices Market Dynamics

Market Growth Drivers

Driving factors in the diabetes care devices market are primarily linked to the escalating prevalence of diabetes worldwide. This increase is largely attributed to rising obesity rates, unhealthy dietary habits, and sedentary lifestyles, which contribute to a higher incidence of diabetes, particularly type 2. According to the National Center for Biotechnology Information (NCBI), if current trends continue, a significant portion of the global population will be overweight or obese by 2035, leading to a surge in diabetes cases. As the demand for effective diabetes management solutions grows, so does the need for advanced diabetes care devices, such as continuous glucose monitoring systems, insulin pumps, and smart insulin pens, which enhance patient outcomes and improve the quality of life for individuals living with diabetes.

Technological advancements are also a crucial driver of market growth. Innovations in diabetes care devices have led to the development of more accurate, convenient, and efficient tools for monitoring blood glucose levels and administering insulin. The integration of smart technology into insulin delivery devices has transformed diabetes management, making it easier for patients to track their health and adhere to treatment plans. Additionally, the increasing adoption of telemedicine and remote monitoring technologies allows healthcare providers to offer more personalized care, further driving the demand for diabetes care devices.

Market Restraints

Despite the positive outlook, the market faces challenges such as limited access to healthcare in rural areas and high costs associated with diabetes care devices. These factors can hinder the adoption of necessary technologies, particularly in underdeveloped regions. However, the overall growth potential remains strong, driven by rising awareness of diabetes management, government initiatives to promote healthy lifestyles, and the continuous innovation of diabetes care devices. As the market evolves, it is expected to witness significant advancements that will enhance the management of diabetes and improve patient outcomes.

Competitive Landscape for Diabetes Care Devices Market in APAC

Key Players

Recent Developments:

In 2022, Dexcom launched the Dexcom G7 continuous glucose monitoring (CGM) system in the US and several European countries. The G7 is 60% smaller than the previous G6 model and features a 30-minute warm-up period.

In 2022,Insulet received FDA clearance for its Omnipod 5 automated insulin delivery system, the first tubeless, wearable system integrated with a smartphone app and compatible with multiple blood glucose devices.

In 2022,Tandem Diabetes Care launched the t:slim X2 insulin pump with Control-IQ technology in several international markets, offering automated insulin delivery based on Dexcom CGM readings.

In 2025, Abbott received CE Mark for its FreeStyle Libre 3 CGM system in Europe, providing real-time glucose readings every minute with improved accuracy compared to fingerstick measurements.

Medtronic launched the MiniMed 780G insulin pump system with advanced hybrid closed-loop technology in several countries, automatically adjusting insulin delivery based on Medtronic CGM data.

In 2025, Eli Lilly and Dexcom announced a strategic collaboration to integrate Dexcom CGM data into Lilly's connected insulin pen solutions, aiming to provide a more comprehensive diabetes management platform

Healthcare Policies and Regulatory Landscape for Diabetes Care Devices Market in APAC

Diabetes Care Devices in APAC: rules, payment and research

In some of the countries we cover here, medical devices are regulated by TGA (Australia)⁠[1], NMPA (China)⁠[2], MDACS (Hong Kong)⁠[3], CDSCO (India)⁠[4], PMDA (Japan)⁠[5], MDA (Malaysia)⁠[6], Medsafe (WAND) (New Zealand)⁠[7], FDA Philippines (Philippines)⁠[8], HSA (Singapore)⁠[9] and Thai FDA (Thailand)⁠[10]. How care is paid for in some of these countries: Medicare and the PBS (Australia)⁠[11], basic medical insurance (China)⁠[12], the Hospital Authority (Hong Kong)⁠[13], Ayushman Bharat PM-JAY (India)⁠[14], public health insurance (Japan)⁠[15], subsidised public care (Malaysia)⁠[16], Pharmac (New Zealand)⁠[17], PhilHealth (Philippines)⁠[18], MediShield Life (Singapore)⁠[19] and the Universal Coverage Scheme (Thailand)⁠[20]. ClinicalTrials.gov lists 144 studies on Diabetes Care Devices that are recruiting, active or about to start in APAC.⁠[21]

[1] Therapeutic Goods Administration. Checked 14 Nov 2026.

[2] National Medical Products Administration. Checked 14 Nov 2026.

[3] Medical Device Division, Department of Health. Checked 14 Nov 2026.

[4] Central Drugs Standard Control Organisation. Checked 14 Nov 2026.

[5] Pharmaceuticals and Medical Devices Agency. Checked 14 Nov 2026.

[6] Medical Device Authority. Checked 14 Nov 2026.

[7] Medsafe. Checked 14 Nov 2026.

[8] Food and Drug Administration Philippines. Checked 14 Nov 2026.

[9] Health Sciences Authority. Checked 14 Nov 2026.

[10] Thai Food and Drug Administration. Checked 14 Nov 2026.

[11] Pharmaceutical Benefits Scheme. Checked 14 Nov 2026.

[12] National Healthcare Security Administration. Checked 14 Nov 2026.

[13] Hospital Authority. Checked 14 Nov 2026.

[14] National Health Authority (PM-JAY). Checked 14 Nov 2026.

[15] Ministry of Health, Labour and Welfare. Checked 14 Nov 2026.

[16] Ministry of Health Malaysia. Checked 14 Nov 2026.

[17] Pharmac. Checked 14 Nov 2026.

[18] PhilHealth. Checked 14 Nov 2026.

[19] CPF Board, MediShield Life. Checked 14 Nov 2026.

[20] National Health Security Office. Checked 14 Nov 2026.

[21] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in APAC. Retrieved 9 Nov 2026.

The healthcare policies and regulatory landscape for the diabetes care devices market is characterized by a framework designed to ensure the safety, efficacy, and accessibility of these essential medical devices. Regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) set stringent guidelines for the approval and monitoring of diabetes care devices. Manufacturers must demonstrate the safety and effectiveness of their products through comprehensive clinical trials and testing before they can enter the market. This regulatory oversight is crucial for maintaining consumer trust and ensuring that patients have access to reliable and effective diabetes management tools.

In addition to regulatory requirements, reimbursement policies significantly influence the adoption of diabetes care devices. In many regions, including those with universal healthcare systems, government support for diabetes management technologies can enhance patient access to necessary devices. Conversely, limited reimbursement for advanced diabetes technologies can hinder their uptake in certain markets. Advocacy from patient groups and healthcare organizations is vital in pushing for broader coverage and reimbursement policies that recognize the value of diabetes care devices in improving patient outcomes.

Furthermore, global initiatives aimed at increasing awareness of diabetes and promoting healthy lifestyles are also impacting the regulatory landscape. Organizations such as the World Health Organization (WHO) and the International Diabetes Federation (IDF) work to raise awareness about diabetes management and the importance of using advanced technologies. These initiatives help to educate healthcare providers and patients, fostering an environment that encourages the adoption of diabetes care devices. Overall, the regulatory landscape is evolving to support the integration of innovative technologies into diabetes management, ultimately aiming to improve patient care and outcomes on a global scale.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Diabetes Care Devices right now, from free public sources.

Clinical trials

144 active trials in China, India, Japan, Australia, Hong Kong, Philippines, Singapore, Thailand, Malaysia, New Zealand, Bangladesh, Afghanistan, Indonesia, Myanmar, Nepal and Pakistan

Recruiting, about to start, or running now. Counted across the 16 countries we report on in APAC.

Top trial sponsors (worldwide)

  1. Sanofi 7 active trials on ClinicalTrials.gov (opens in a new tab)
  2. Abbott Laboratories 5 active trials on ClinicalTrials.gov (opens in a new tab)
  3. Dexcom, Inc. 5 active trials on ClinicalTrials.gov (opens in a new tab)
  4. Novo Nordisk A/S 3 active trials on ClinicalTrials.gov (opens in a new tab)
  5. Insulet Corporation 3 active trials on ClinicalTrials.gov (opens in a new tab)

Source: ClinicalTrials.gov, Industry lead sponsors of active studies found with this market's trial search, worldwide. Retrieved 13 Nov 2026.

See every trial on ClinicalTrials.gov (opens in a new tab)

Patients

Diabetes (adults), % of adults (WHO)
CountryValueYear
Afghanistan25.32022
Australia8.12022
Bangladesh17.92022
China11.22022
India22.62022
Indonesia12.82022
Japan6.42022
Malaysia26.72022
Myanmar13.82022
Nepal15.82022
New Zealand9.02022
Pakistan30.92022
Philippines13.22022
Singapore13.12022
Thailand12.32022
Compare every country on the Public Health Dashboard

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, WHO Global Health Observatory. Fetched 15 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Diabetes Care Devices in context

Free data on this topic

Quick answers

Frequently asked questions

How big is the Diabetes Care Devices market in Asia Pacific?
Placeholder estimate: about $10.27 Bn in 2025, rising to about $19.16 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Diabetes Care Devices market in Asia Pacific growing?
Placeholder estimate: about 7.17% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Diabetes Care Devices market report cover?
The report splits the market by product type (Blood Glucose Monitoring Devices, Insulin Delivery Devices), device type (Self-monitoring, Diagnostic), delivery type (Pumps, Pen, Syringes, Injectors and more) and distribution channel (Institutional Sales, Retail Sales).
Who are the key players in the Diabetes Care Devices market?
Key players include Medtronic, Abbott Laboratories, Dexcom, Inc., Roche Diabetes Care, Novo Nordisk A/S and Ascensia Diabetes Care, among 10 companies the report profiles.
What is driving the Diabetes Care Devices market?
Driving factors in the diabetes care devices market are primarily linked to the escalating prevalence of diabetes worldwide. This increase is largely attributed to rising obesity rates, unhealthy dietary habits, and sedentary lifestyles, which contribute to a higher incidence of diabetes, particularly type 2.
How many clinical trials on Diabetes Care Devices are running in Asia Pacific?
144 studies are recruiting, active or about to start in Asia Pacific, counted across the 16 countries we report on there, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Asia Pacific. Retrieved 9 Nov 2026.
How much research is published on Diabetes Care Devices?
PubMed lists 8,417 papers on Diabetes Care Devices added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 9 Nov 2026.
Back to Catalogue

Related Medical Devices reports in APAC

See all

Related on diabetes

See the topic